{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:47:27Z","timestamp":1776314847966,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study describes clinical characteristics, treatment patterns as well as safety outcomes of NSCLC patients harboring PD-L1\u2009\u2265\u200950% who received adjuvant atezolizumab within the Italian real-world scenario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with surgically resected NSCLC harboring EGFR\/ALK wild type disease and PD-L1 TPS \u2265 50%, who received at least one cycle of adjuvant atezolizumab were included. Clinical-pathological and molecular data, safety and efficacy outcomes were collected from the Italian ATLAS real-world registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 132 patients were included across 45 Italian centers between July 2022 and August 2024. Lobectomy was performed in 81.1% of cases, with 8.3% pathological stage IIA, 40.2% stage IIB, 43.9% stage IIIA, and 7.6% stage IIIB, according to the eighth TNM staging edition. The median number of atezolizumab cycles was 12.5 (range: 1-20). Treatment related adverse events (TRAEs) during atezolizumab were reported in 44 patients (33.3%), including 11 (8.3%) who experienced multiple TRAEs. Grade \u2265 3 TRAEs were reported in 21 cases (15.9%), leading to treatment discontinuation in 18 (13.6%). The median time to the first onset of TRAEs was 89\u2009days (range: 3-390\u2009days). 15 patients experienced a disease recurrence, including 6 locoregional-only and 9 distant relapses, with a median time since surgery of 13.3\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that the safety profile of adjuvant atezolizumab outside of a clinical trial context was comparable to the IMPower-010 study, highlighting the value of the Italian ATLAS registry as source of real-word evidence to optimize the clinical management of NSCLC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf428","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T12:55:12Z","timestamp":1766494512000},"source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression \u2265 50%: real-world data from the Italian ATLAS registry"],"prefix":"10.1093","volume":"31","author":[{"given":"Francesco","family":"Passiglia","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Hospital , Orbassano, TO 10043,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia","family":"Reale","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, \u201cVito Fazzi\u201d Hospital , Lecce 73100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"DiSCOG University of Padua , Padova 35122,","place":["Italy"]},{"name":"Oncology Unit 2, IOV Istituto Oncologico Veneto IRCCS , Padova 35128,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-9387","authenticated-orcid":false,"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[{"name":"UOC Pneumologia Oncologica, AORN Azienda Ospedaliera Dei Colli Monaldi , Napoli 80131,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Attili","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS , Milan 20141,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"Department of Oncology, Careggi University Hospital , Florence 50134,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Galetta","sequence":"additional","affiliation":[{"name":"Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II , Bari 70124,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2926-4663","authenticated-orcid":false,"given":"Chiara","family":"Catania","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Humanitas Gavazzeni , Bergamo 24125,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kallopi","family":"Andrikou","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d , Meldola 47014,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Humanitas Istituto Clinico Catanese , Catania 95045,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Vavala","sequence":"additional","affiliation":[{"name":"Department of Oncology, AOU Citt\u00e0 della Salute e della Scienza, SC Oncologia 1U , Torino 10126,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-4813","authenticated-orcid":false,"given":"Alessandra","family":"Bulotta","sequence":"additional","affiliation":[{"name":"Department of Oncology, IRCCS Ospedale San Raffaele , Milan 20132,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Calvetti","sequence":"additional","affiliation":[{"name":"Medical Oncology, San Bortolo Hospital, Vicenza 36100, \u00a0","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Carta","sequence":"additional","affiliation":[{"name":"SC Oncologia Medica, Ospedale Businco ARNAS G. Brotzu, Cagliari 09121, \u00a0","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Spedali Civili di Brescia, Univeristy of Brescia , Brescia 25123,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Medical Oncology, Department of Onco-Hematology, Azienda Ospedaliera Policlinico Tor Vergata, University of Rome Tor Vergata , Rome 00133,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"La Cava","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University , Rome 00128,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Dodi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma , Parma 43121,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vieri","family":"Scotti","sequence":"additional","affiliation":[{"name":"Azienda Ospedaliero-Universitaria Careggi , Florence 50134,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Del Giudice","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, AOU Renato Dulbecco , Catanzaro 88100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Minuti","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit: Phase 1 and Precision Medicine, National Cancer Institute, IRCCS, Regina Elena , Rome 00144,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elio Gregory","family":"Pizzutillo","sequence":"additional","affiliation":[{"name":"Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda , Milan 20162,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[{"name":"UOC Oncologia AST PU\u2014Pesaro e Fano , Pesaro 61121,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carminia Maria","family":"Della Corte","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, Universit\u00e0 degli studi della Campania \u201cLuigi Vanvitelli\u201d , Naples 80131,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, University of Genoa , Genoa 16132,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[{"name":"Thoracic Unit, Department of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano , Milano 20133,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Pignataro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cardinal Massaia Hospital , Asti 14100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Pozzessere","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, S. Stefano Hospital, Azienda USL Toscana Centro, Prato 59100, \u00a0","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Roca","sequence":"additional","affiliation":[{"name":"Thoracic Oncology\u2014Lung Unit, P. Pederzoli Hospital, Peschiera Del Garda (VR) 37019,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Toschi","sequence":"additional","affiliation":[{"name":"IRCCS Humanitas Clinical and Research Center\u2014Humanitas Cancer Center, Rozzano , Milan 20089,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Bennati","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale Santa Maria delle Croci , Ravenna 48121,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Borra","sequence":"additional","affiliation":[{"name":"Medical Oncology, Maggiore della Carit\u00e0 Hospital , Novara 28100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bettini","sequence":"additional","affiliation":[{"name":"Medical Oncology, ASST Papa Giovanni XXIII , Bergamo 24127,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Favaretto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AULSS 2 Marca Trevigiana, Ca\u2019Foncello Hospital , Treviso 31021,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Gelibter","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome , Rome 00185,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-405X","authenticated-orcid":false,"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella , Verona 37024,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Tabb\u00f2","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, ASLCN2 Alba e Bra\u2014Michele e Pietro Ferrero Hospital , Verduno 12060,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pagano","sequence":"additional","affiliation":[{"name":"Oncologia Medica, IRCCS Arcispedale Maria Nuova Reggio Emilia , Reggio Emilia 42123,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Pavan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AULSS 3 Serenissima , Venezia 30174,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Belluomini","sequence":"additional","affiliation":[{"name":"Section of Innovation Biomedicine\u2014Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona , Verona 37126,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Tondulli","sequence":"additional","affiliation":[{"name":"Oncologia Medica, Azienda Sanitaria dell\u2019Alto Adige , Bolzano 39100,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Sergi","sequence":"additional","affiliation":[{"name":"Oncology Unit, ARNAS Garibaldi Nesima , Catania 95123,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS , Aviano 33081,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[{"name":"Department of Public Health, University Federico II of Naples , Naples 80138,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, San Luigi Hospital , Orbassano, TO 10043,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2333-704X","authenticated-orcid":false,"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Universit\u00e0 Cattolica del Sacro Cuore, Rome 00168,","place":["Italy"]},{"name":"Ospedale Isola Tiberina\u2014Gemelli Isola , Rome 00186,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026012919065598100_oyaf428-B1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026012919065598100_oyaf428-B2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jtho.2024.01.019","article-title":"The International Association for the study of lung cancer lung cancer staging project: Proposal for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification of lung cancer","volume":"19","author":"Fong","year":"2024","journal-title":"J Thorac Oncol"},{"key":"2026012919065598100_oyaf428-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026012919065598100_oyaf428-B4","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026012919065598100_oyaf428-B5","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012919065598100_oyaf428-B6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"2026012919065598100_oyaf428-B7","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012919065598100_oyaf428-B8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012919065598100_oyaf428-B9","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"2026012919065598100_oyaf428-B10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable Non-Small cell lung cancer: the Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"key":"2026012919065598100_oyaf428-B11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026012919065598100_oyaf428-B12","first-page":"S1722","author":"Wakelee","year":"2025"},{"key":"2026012919065598100_oyaf428-B13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026012919065598100_oyaf428-B14","doi-asserted-by":"publisher","first-page":"S1238","DOI":"10.1016\/j.annonc.2024.08.2289","article-title":"CCTG BR.31: a global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","volume":"35","author":"Goss","year":"2024","journal-title":"Ann Oncol"},{"key":"2026012919065598100_oyaf428-B15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"key":"2026012919065598100_oyaf428-B16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026012919065598100_oyaf428-B17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jtcvs.2023.01.012","article-title":"Safety of adjuvant atezolizumab after pneumonectomy\/bilobectomy in stage II-IIIA non\u2013small cell lung cancer in the randomized phase III IMpower010 trial","volume":"166","author":"Lee","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026012919065598100_oyaf428-B18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf428\/66125865\/oyaf428.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf428\/66125865\/oyaf428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf428\/66125865\/oyaf428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:07:07Z","timestamp":1769731627000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf428\/8404481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf428","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,24]]},"article-number":"oyaf428"}}